# Graybug Vision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/graybug-vision

- Industry: Pharmaceuticals
- Headquarters: Redwood City, US
- Website: www.graybug.vision
- Total disclosed funding: $79M
- Latest round: Series C (Jul 31, 2019)
- Investors on record: 8

## About

Founded in 2011 and based in California, US, Graybug Vision, Inc. is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of ocular diseases such as glaucoma and corneal graft rejection. The company offers GB-102, a clinical-stage depot formulation for the treatment of wet age0-related degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).

## Funding rounds

- Series C, Jul 31, 2019, $55M — OrbiMed Advisors, Hatteras Venture Partners, Clarus Ventures, Deerfield Management, CBC Group
- Series B, Apr 29, 2016, $21M — OrbiMed Advisors, Hatteras Venture Partners, Clarus Ventures, Deerfield Management
- Series A, Mar 9, 2015, $1.7M — Hatteras Venture Partners, Maryland Venture Fund
- Series A, Oct 29, 2013, $1.5M — Abell Foundation, Brown Advisory, Maryland Venture Fund

## Investors

- Abell Foundation — Series A
- Brown Advisory — Series A
- Maryland Venture Fund (https://capitalatlas.ai/funds/maryland-venture-fund) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B, Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B, Series C
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series C